Inflation Update)
H.B. Fuller to implement 11% price increase on product shipments globally 07:35 FUL
Levi Strauss initiated with an Overweight at Wells Fargo 05:49 LEVI
Ok NXRP is up 9-10% in the pre at $15 now--
NRx Pharma jumps 10% after Zyesami shows relief from respiratory distress due to COVID-19.... Ok DEEP DIVE-!
we know that
Zyesami (Aviptadil) is a formulation of synthetic human Vasoactive IntestinalPeptide(VIP), which was first discovered in 1970.
and we know.... NRXP has a partner.... tiny Relief Therapeutics Holding AG (RLFTF)
RLF-100 has received the Fast Track designation from the FDA and is under development in cooperation with the National Institute of Health and other federal agencies.
Relief and NeuroRx are working on a partnership basis which is a strong positive.
Hence, the companies have agreed to share all profits from sales on a 50/50 basis in the U.S., Canada and Israel. It will be 85/15 in favor of Relief in Europe and 80/20 (in favor of Relief) in all other territories.
As for commercial manufacturing of the Aviptadil drug substance, the partners have contracted Nephron Pharmaceuticals, should the clinical trials demonstrate safety and efficacy.
Ok so why no action on Relief?
Relief Therapeutics Holding AG (RLFTF)
0.2012-0.0013 (-0.64%)
At close: August 27
H.B. Fuller to implement 11% price increase on product shipments globally 07:35 FUL
Levi Strauss initiated with an Overweight at Wells Fargo 05:49 LEVI
Ok NXRP is up 9-10% in the pre at $15 now--
NRx Pharma jumps 10% after Zyesami shows relief from respiratory distress due to COVID-19.... Ok DEEP DIVE-!
we know that
Zyesami (Aviptadil) is a formulation of synthetic human Vasoactive IntestinalPeptide(VIP), which was first discovered in 1970.
and we know.... NRXP has a partner.... tiny Relief Therapeutics Holding AG (RLFTF)
RLF-100 has received the Fast Track designation from the FDA and is under development in cooperation with the National Institute of Health and other federal agencies.
Relief and NeuroRx are working on a partnership basis which is a strong positive.
Hence, the companies have agreed to share all profits from sales on a 50/50 basis in the U.S., Canada and Israel. It will be 85/15 in favor of Relief in Europe and 80/20 (in favor of Relief) in all other territories.
As for commercial manufacturing of the Aviptadil drug substance, the partners have contracted Nephron Pharmaceuticals, should the clinical trials demonstrate safety and efficacy.
Ok so why no action on Relief?
Relief Therapeutics Holding AG (RLFTF)
0.2012-0.0013 (-0.64%)
At close: August 27